VIVS VivoSim Labs, INC.

Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001497253
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

VivoSim Labs exhibits critical financial distress with a non-viable operating model: $8.3M operating losses on only $91K in revenue represents a fundamental breakdown in business economics. Current cash burn of $8.6M annually depletes the $4.3M cash position within months, creating imminent solvency risk without significant capital raises or dramatic revenue acceleration.

Strengths

  • + No debt burden provides flexibility for capital structure
  • + Adequate short-term liquidity with 2.44x current ratio
  • + Revenue growing 32.1% YoY indicates emerging sales traction

Risks

  • ! Operating loss of $8.3M on $91K revenue is unsustainable and indicates business model failure
  • ! Cash runway of ~6 months at current burn rate with imminent depletion risk
  • ! Operating margin of -9121% and ROA of -116% show severe capital inefficiency
  • ! Pre-commercial stage with zero path to near-term profitability
  • ! Stockholder equity at risk of substantial dilution through future capital raises

Key Metrics to Watch

Financial Metrics

Revenue
91.0K
Net Income
-8.1M
EPS (Diluted)
$-3.14
Free Cash Flow
-8.6M
Total Assets
7.0M
Cash
4.3M

Profitability Ratios

Gross Margin N/A
Operating Margin -9,120.9%
Net Margin -8,878.0%
ROE -181.9%
ROA -116.1%
FCF Margin -9,438.5%

Balance Sheet & Liquidity

Current Ratio
2.44x
Quick Ratio
2.44x
Debt/Equity
0.00x
Debt/Assets
36.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-18T17:03:21.427038 | Data as of: 2025-12-31 | Powered by Claude AI